Dr. Mark J. Fesler, MD | Chesterfield ...

Dr. Mark J. Fesler

Claim this profile

Saint Luke's Hospital

Studies Lymphoma
Studies Mantle Cell Lymphoma
12 reported clinical trials
32 drugs studied

Area of expertise

1Lymphoma
Mark J. Fesler has run 4 trials for Lymphoma. Some of their research focus areas include:
BCL6 positive
MYC positive
BCL2 positive
2Mantle Cell Lymphoma
Mark J. Fesler has run 3 trials for Mantle Cell Lymphoma. Some of their research focus areas include:
CCND1 positive
t(11;14) positive
Stage I

Affiliated Hospitals

Image of trial facility.
Saint Luke's Hospital
Image of trial facility.
St. Luke's Center For Cancer Care

Clinical Trials Mark J. Fesler is currently running

Image of trial facility.

Zanubrutinib

for Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria

More about Mark J. Fesler

Clinical Trial Related8 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Mark J. Fesler has experience with
  • Rituximab
  • Cyclophosphamide
  • Dexamethasone
  • Autologous Hematopoietic Stem Cell Transplantation
  • Prednisone
  • Vincristine Sulfate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Mark J. Fesler specialize in?
Is Mark J. Fesler currently recruiting for clinical trials?
Are there any treatments that Mark J. Fesler has studied deeply?
What is the best way to schedule an appointment with Mark J. Fesler?
What is the office address of Mark J. Fesler?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security